Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Apr 10, 2024 · Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …
A comprehensive evaluation of ALK inhibitors in the first-line ...
Mar 1, 2025 · There are currently six ALK inhibitors available for the first-line treatment of patients diagnosed with ALK-positive advanced non-small cell lung cancer (NSCLC). However, clinicians …
Targeted Drug Therapy for Non-small Cell Lung Cancer
Examples of ALK inhibitors: Third-generation ALK inhibitor [lorlatinib (Lorbrena)] and second-generation ALK inhibitors [alectinib (Alecensa), brigatinib (Alunbrig), ceritinib (Zykadia), and …
Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: …
Sep 30, 2023 · ALK–rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use. Little is known about …
Treatment Options for ALK+ - ALK Positive
What to Know About ALK Targeted Therapies (TKIs) For most patients diagnosed with advanced ALK+ lung cancer, medical guidelines in the United States, and around the world, now …
ALK Inhibitors in the Treatment of ALK Positive NSCLC
Jan 9, 2019 · Conclusions: Overall ALK inhibitors are safe and effective treatment option in ALK+ non-small cell lung cancer. Of the ALK inhibitors, Next generation agents in particular alectinib …
ALK+ NSCLC Treatment Guidelines
Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy.
Lorlatinib Versus Crizotinib in Patients With Advanced ALK
May 31, 2024 · Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy recommended for patients with ALK -positive non–small cell lung …
Alectinib in combination with bevacizumab as first-line treatment …
May 16, 2025 · Next-generation ALK - TKIs have become the standard first-line treatment option for patients with advanced ALK -positive NSCLC because of their greater potency, selectivity, …
Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC
Jul 10, 2024 · A major question for both patients and health care providers, Dr. Zhao said, is whether to use lorlatinib or another ALK inhibitor, such as alectinib, as initial treatment for …
Skip to content